Pfizer Restructuring a Boon to CMOs and CROs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
Pfizer Restructuring a Boon to CMOs and CROs
As big pharmaceutical companies restructure and reevaluate the way they do business, contract research and manufacturing organizations could reap greater financial rewards.
Mar 2, 2007
By: Jim Miller
Pharmaceutical Technology

« Previous
123

On the basis of its past history, Blackstone is likely to hold on to PTS for three to five years, perhaps acquiring additional businesses to add to its offerings. With the favorable industry market conditions and PTS's major investments nearly completed (especially in sterile manufacturing), Blackstone is entering the contract manufacturing and development business at an especially propitious time.

Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report, tel. 703.383.4903, fax 703.383.4905, info@pharmsource.com
, http://www.pharmsource.com/.

« Previous
123

ADVERTISEMENT
RELATED CONTENT
Pfizer Plans Additional Cost Cutting
AnorMED accepts Genzyme's Offer of US $13.50 a Share
Merck KGaA to Acquire Majority Stake in Serono for $13.3 Billion
PhRMA Names New Chairman
Chemir Launches IQsynthesis
blog comments powered by Disqus
About the Author

Jim Miller

Outsourcing Outlook

http://www.pharmsource.com

Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report, a monthly newsletter covering the contract drug development industry. A trial subscription can be obtained by calling 703.383.4903, by faxing 703.383.4905, by e-mailing info@pharmsource.com, or on the Web at www.pharmsource.com. Articles by Jim Miller
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
20%
Do not use QbD
25%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
FindPharma Custom Search
Featured Jobs

More Jobs
Source: Pharmaceutical Technology, 3/2/2007
 Click here